Looking to gene therapy for ocular diseases, with Lance Bald...
Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
Newsletters and Deep Dive digital magazine
Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development.
Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.
One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Ongoing work in Morocco demonstrates how developing research infrastructure can support innovative approaches grounded in locally generated data.
Editor's Picks
Newsletters and Deep Dive
digital magazine